Lokon Pharma focuses on the development of LOAd therapy for different types of cancer and in combination with other cancer therapeutics including chemotherapy and checkpoint blockade antibody therapy.
Besides the clinical stage LOAd703 virus, the LOAd family includes a range of novel tumor microenvironment (TME) gene engineering vectors that are currently being evaluated for mechanisms-of-action (MOA) and proof-of-concept (POC).
